Obesity in companion animals is a growing problem for our furry friends. Over 60% of U.S. dogs and cats are now classified as overweight or obese, placing them at heightened risk for conditions such as osteoarthritis, endocrine disorders, cardiovascular dysfunction, and insulin resistance. These realities are reshaping the landscape of veterinary medicine and product innovation alike.

Chronic Disease Calls for Chronic-Use Solutions and Safety That Lasts

As the industry responds with therapeutic diets, long-acting injectables, and metabolic modulators, the path from concept to clinic demands more than innovation. It requires preclinical safety data that withstands regulatory scrutiny and mirrors the complex reality of treating aging, overweight pets over time.

Safety isn’t a one-time check; it’s a longitudinal commitment. Chronic-use therapeutics must undergo robust evaluations that go well beyond acute tolerability. Critical areas of investigation include:

• Multi-systemic toxicity across liver, kidney, cardiovascular, and endocrine systems
• Pharmacokinetic behavior in obese versus with in healthy weight range of pets
• Impact of co-morbidities, including metabolic or orthopedic disorders that may influence absorption, distribution, metabolism, and excretion
• Age and weight class considerations, which increasingly factor into safety modeling

Translating Real-World Use into Regulatory-Ready Data

Effective preclinical development means designing studies that reflect how these products will actually be used, repeatedly, across varied patient populations, and often in combination with other treatments. That includes:

• Chronic and Subchronic Toxicology Studies in companion species
• Dose Range Finding and repeat-dose protocols tailored to therapeutic class and target indication
• Customized models that account for obesity-driven physiological variability
• Full-service support from protocol design through GLP-compliant reporting and submission support

Why Choose Attentive Science?

Attentive Science supports the development of chronic-use veterinary therapeutics with a safety-first mindset, because long-term care starts with knowledge of long-term data. Our scientific leadership and operational structure allow us to work closely with sponsors to ensure that every study produces not just data, but decision-making clarity.

We’re built for collaboration, grounded in regulatory expectations, and driven by science that leads to clear decisions. Whether you're exploring novel therapies or expanding indications, we’ll help you generate the data you need—on time, on budget, and with precision.

If you're looking for shortcuts or less robust data when it comes to the health of companion pets, then Attentive Science IS NOT the right fit for you. But if you’re seeking a partner who is as thorough, detailed, and attentive as your product demands, then WE ARE exactly who you're looking for.

At Attentive Science, we combine rigor, responsiveness, and veterinary expertise to help you bring safe and effective chronic-use products to a growing population of pets in need. Let’s advance companion animal health together.

Contact us to Discover what makes Attentive different.